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Context: Ferritin concentration is associated with metabolic syndrome, but the possibility of a
nonlinear association has never been explored.
Objective: This study aimed to examine the relationship between serum ferritin levels and the
metabolic syndrome in Spanish adult males.
Design:Thiswas a cross-sectional analysis of baselinedata from theAragonWorkers’ Health Study.
Setting: Healthy workers from a factory were studied during their annual checkup.
Participants: Spanishmale adults (n 3386) between the ages of 19 and 65 years participated.We
excluded participants with ferritin 500 g/L, ferritin 12 g/L, or C-reactive protein 10 mg/L.
Main Outcome Measure:Metabolic syndrome was defined according to the 2009 consensus def-
inition from the Joint Interim Statement of several international societies.
Results: Metabolic syndrome prevalence was 27.1%. We found a positive association between
elevated iron stores, measured as serum ferritin concentration, and metabolic syndrome and its
criteria. Participants within the highest serum ferritin quintile had a higher risk than those in the
lowest quintile for central obesity (odds ratio [OR], 1.88; 95% confidence interval [CI], 1.46–2.42),
hypertriglyceridemia (OR, 2.15; 95% CI, 1.69–2.74), and metabolic syndrome (OR, 1.92; 95% CI,
1.48–2.49). Theassociationwasnonlinear andoccurredat serumferritin concentrations100g/L
( 33th percentile). Ferritin was also associated with insulin resistance, measured by homeostatic
model assessment–insulin resistance (HOMA-IR) (P trend  .001).
Conclusions: Our findings suggest that serum ferritin is significantly associated with metabolic
syndrome and its criteria (especially central obesity and hypertriglyceridemia), suggesting that
ferritin could be an earlymarker ofmetabolic damage in thedevelopment ofmetabolic syndrome.
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Iron is essential for multiple biological processes, amongthemost importantbeingoxygen transport and inflam-
mation. The role of iron in inflammation is related to the
production of free radicals and oxidative stress. More-
over, chronic inflammation and oxidative stress are im-
portant in the pathogenesis and progress ofmetabolic syn-
drome, and iron may be involved in this process. In
humans, serum ferritin concentration correlates with
body iron stores, giving a more precise stores’ measure-
ment than direct quantification of iron in serum.
Cross-sectional studies have shown associations of el-
evated serum ferritin concentration with metabolic syn-
drome (1–3), hypertension, dyslipidemia, elevated fasting
insulin, high blood glucose, and central adiposity (4–6).
Increased serum concentrations of ferritin is also associ-
ated with insulin resistance, type 2 diabetes mellitus, and
metabolic syndrome in men (7, 8). Previous studies have
only studied the linear association between elevated iron
stores and metabolic syndrome, and there is little infor-
mation regarding the level of ferritin at which this asso-
ciation begins to appear, under the hypothesis that the
association is nonlinear.
We performed a cross-sectional analysis of the associ-
ation of serum ferritin andmetabolic syndrome in Spanish
adult male participants in the Aragon Workers’ Health
Study, using methods to detect a nonlinear relationship.
Materials and Methods
The Aragon Workers’ Health Study (AWHS) is a longi-
tudinal cohort study of cardiovascular risk factors and
subclinical atherosclerosis (9) among workers at the Gen-
eral Motors factory in Figueruelas (Zaragoza), Spain. All
workerswere invited toparticipate, and5456participants
had been recruited at the time of the analysis. All partic-
ipants gave written informed consent, and the study was
approved by the Aragon regional government’s Ethics
Committee for Clinical Research (CEICA). We restricted
our analysis to male participants (N 5104). Participant
age range was 19–65 years. A total of 1417 participants
were excluded for missing data: 436 for ferritin; 212 for
criteria required for diagnosis of metabolic syndrome
(waist circumference, triglycerides, high-density lipopro-
tein [HDL] cholesterol, blood pressure [BP], and fasting
glucose); and 769 for relevant covariables (body mass in-
dex, insulin, C-reactive protein [CRP], serum iron, and
information onblooddonation). ParticipantswithCRP
10 mg/L (N  127) were excluded because ferritin is ele-
vated in acute inflammatory processes. We also excluded
participants with serum iron  190 g/dL or ferritin 
500 g/L (N  144) because of probable hemochroma-
tosis and thosewith ferritin 12g/L (N 30). The final
sample size was 3386.
Data collection
Information on sex, age, history of blood donation, alcohol
intake, and use of medication was based on clinical interview,
questionnaires and self reporting. Blood pressure was estimated
as the mean of three consecutive measurements made with an
automatic oscillometric sphygmomanometerOMRONM10-IT
(OMRONHealthcareCo. Ltd, Kyoto, Japan), after 5minutes of
sitting. The physical examination included height, weight, and
waist circumference, which was measured with the participant
standing, at a plane in the midpoint between the ilium and the
costal border.
Laboratory measurements
Peripheral venous blood samples were collected after an
8-hour fast. All biochemistry assays were measured in serum.
Ferritin was measured using the Quantex Ferritin Kit (BIOKIT,
Barcelona, Spain), which is based on an antigen-antibody reac-
tion detected by turbidimetry in an ILAB650 analyzer (Instru-
mentation Laboratory, Bedford, MA). Triglycerides, HDL
cholesterol, total cholesterol, fasting glucose, aspartate amino-
transferase (AST), and alanine aminotransferase (ALT) were
measured in spectrophotometric assays in the ILAB650analyzer,
using the manufacturer’s kits (Instrumentation Laboratory). In-
sulin concentration was measured by double sandwich immu-
noassay in frozen samples in an Access 2 Analyzer (Beckman
Coulter, Inc., Fullerton, CA) using the manufacturer’s ultrasen-
sitive kit. CRP concentration was measured by turbidimetric
immunoassay in a Beckman Coulter Immage Analyzer using the
manufacturer’s high-sensitivity kit. Low-density lipoprotein
(LDL) cholesterol was estimated from the Friedewald formula,
and homeostatic model assessment–insulin resistance (HOMA-
IR) was calculated as glucose (mg/dL) multiplied by insulin
(mU/L) divided by 405 (10). Blood extraction and anthropomet-
ric and biochemicalmeasurements in this study are certifiedwith
the International Organization for Standardization standard
ISO 9001:2008.
Metabolic syndrome criteria
Individuals were diagnosed as having metabolic syndrome
according to the consensus definition in the 2009 joint interim
statement of the International Diabetes Federation Task Force
on Epidemiology and Prevention, theNationalHeart, Lung, and
Blood Institute, the American Heart Association, the World
Heart Federation, the International Atherosclerosis Society, and
the International Association for the Study ofObesity (11).Met-
abolic syndrome was diagnosed when subjects met at least three
of the five followingmetabolic syndrome criteria (MSC): central
obesity (waist circumference  102 cm), hypertriglyceridemia
( 1.7 mmol/L [ 150 mg/dL] or drug treatment for elevated
triglycerides), low HDL cholesterol ( 1.03 mmol/L [ 40 mg/
dL] or drug treatment for depressed HDL-cholesterol concen-
tration), hypertension (systolic BP 130mmHg, diastolic BP
85 mmHg, or antihypertensive drug treatment in a patient with
a history of hypertension), and hyperglycemia (5.6 mmol/L
[100 mg/dL] or drug treatment for elevated glucose). From
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here on, we denote these variables with the suffix MSC (meta-
bolic syndrome criterion) to distinguish them from general clin-
ical situations with the same name.
Statistical analysis
Participants were divided into quintiles of ferritin concen-
tration based on the sample distribution. Transaminases (ALT
andAST) were categorized according to reference values (nor-
mal:  40 U/L; high normal: 40–100 U/L; high:  100 U/L).
HOMA-IR was log transformed. Adjusted mean differences
between the lowest ferritin concentration quintile and each of
the other quintiles were calculated using multivariable linear
regression. For dichotomous variables, interquintile odds ra-
tios (ORs) were calculated by multivariable logistic regres-
sion. Models were adjusted for age (continuous), history of
blood donation (as a dichotomous variable), transaminase
activity (categorized as above) and daily alcohol intake (con-
tinuous) (Model 1). Models were further adjusted for contin-
uous metabolic syndrome parameters (waist circumference,
systolic BP, diastolic BP, fasting glucose, triglycerides, and
HDL cholesterol) omitting some of them in case they would
introduce colinearity (Model 2).
To further explore the shape of the relationship between fer-
ritin levels and metabolic syndrome, we used restricted cubic
splines with knots at ferritin concentration percentiles 5, 27.5,
50, 72.5, and 95 in a logistic model adjusted in the same way as
Model 1. The changes observed in slope were confirmed with a
linear spline with knots at 100 and 300 g/L (percentiles 27.7
and86.3). To assess the potential importance of inflammation as
confounder of the relationship between ferritin and metabolic
syndrome, we performed a sensitivity analysis adjusting our
models for CRP. All statistical analyses were performed with
STATA (version 11.1; StataCorp, College Station, TX).
Results
Baseline characteristics
Metabolic syndromeprevalence in this sample ofwork-
ing males was 27.1%. Mean ferritin concentration (SD)
was 201.4 (114.2) g/L among study participants with
metabolic syndrome and 163.8 (101.6)g/L among those
without it. Participants with metabolic syndrome were
more likely to be older (Table 1).
Association between serum ferritin concentration
and metabolic syndrome
Ferritin concentration increased together with age,
body mass index, waist circumference, total cholesterol,
triglycerides, systolic and diastolic BP, serum glucose, and
log-HOMA-IR, and decreased with increasing HDL cho-
lesterol (Table 2). The association was statistically signif-
icant after adjusting for age, transaminase activity, history
of blood donation, and alcohol intake (Model 1).
To investigate an independent association of ferritin
with particular metabolic syndrome traits, we adjusted
each continuous metabolic syndrome variable for the
other metabolic syndrome variables (Model 2). Compar-
ing the highest ferritin quintile ( 261 g/L) to the lowest
( 83 g/L), the adjusted differences (95% confidence
interval [CI]) were statistically significant for waist cir-
cumference [3.01 (2.06–3.95) cm] and for triglycerides
[27.84 (17.97–37.70) mg/dL] (Table 3).
We also calculated the ORs for metabolic syndrome
and each of its criteria across ferritin quintiles through
Table 1. Characteristics of the Study Population and Subpopulations With and Without Metabolic Syndrome
Total
Without Metabolic
Syndrome
With Metabolic
Syndrome P
N 3386 2469 917
Age, years 48.9 (8.7) 47.6 (9.4) 52.2 (5.2) .001
Ferritin, g/L 174.0 (106.4) 163.8 (101.6) 201.4 (114.2) .001
BMI, kg/m2 27.6 (3.6) 26.6 (3.0) 30.3 (3.6) .001
Waist circumference, cm 96.9 (9.7) 94.0 (8.4) 104.8 (8.8) .001
Total cholesterol, mg/dL 212.0 (37.6) 209.7 (37.2) 218.2 (38.1) .001
Triglycerides, mg/dL 142.9 (92.1) 120.8 (71.2) 202.5 (113.1) .001
HDL cholesterol, mg/dL 52.7 (10.9) 54.5 (10.7) 47.8 (10.0) .001
LDL cholesterol, mg/dLa 131.4 (31.9) 131.2 (31.9) 132.0 (32.0) .503
Systolic BP, mm Hg 126.4 (14.4) 123.7 (13.2) 133.9 (15.1) .001
Diastolic BP, mm Hg 83.4 (9.8) 81.1 (9.2) 89.4 (8.9) .001
Fasting glucose, mg/dL 98.0 (18.0) 94.2 (14.1) 108.3 (22.6) .001
HOMA-IR 1.7 (1.5) 1.4 (1.0) 2.6 (2.1) .001
AST, U/L 24.8 (10.6) 24.5 (11.6) 25.6 (7.3) .006
ALT, U/L 27.8 (12.8) 26.0 (11.8) 32.4 (14.3) .001
Daily alcohol intake, g/week 65.2 (59.8) 61.9 (57.8) 74.0 (63.9) .001
Blood donation history, % 17.9 18.4 16.4 .162
Abbreviation: BMI, body mass index.
Data are shown as means (SD) for clinical, physical, and biochemical parameters. For blood donation history, percentage of donors. P values were
calculated from simple unadjusted t tests.
a n  3313 due to missing values.
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a logistic model adjusted in the same way as Model 1.
The adjusted OR (95% CI) for metabolic syndrome
comparing individuals in the highest serum ferritin
quintile with those in the lowest was 1.92 (1.48–2.49)
(Table 4). The multivariable model showed a signifi-
cantly graded relationship between serum ferritin con-
centration and individual metabolic syndrome criteria
(Table 4). The risk of all individual metabolic syndrome
criteria increased with increasing serum ferritin quin-
tile; however, the statistical significance of the HDL
cholesterol criterion was at the limit (Table 4). The cu-
bic spline model showed a tendency toward flatness in
the lower third of the ferritin distribution, whereas a
steep increase was observed at higher levels (Figures 1
and 2). Based on observations in the cubic spline model,
we decided to apply a linear spline function, with knots
at 100 and 300 g/L serum ferritin. The odds slope for
metabolic syndrome changed significantly at 100 g/L
(P  .048). The association at ferritin concentrations
below 100 g/L was not statistically significant (P 
Table 2. Raw Means and Adjusted Differences (95% CI) between the Lowest (First) Ferritin Quintile and the Other
Four Quintiles for Physiological Parameters Related to Metabolic Syndrome
Variable
Quintile of Ferritin Concentration (Interval in g/L)
P
Trend
1st
(< 83)
2nd
(83–127)
3rd
(128–180)
4th
(181–261)
5th
(>261)
N 681 680 672 677 676
Age, y 49.0 47.7 48.5 48.8 50.3
Ferritin, g/L 51.4 104.8 152.6 217.6 344.7
BMI, kg/m2 27.01 27.08 27.42 27.72 28.69
Difference 0.00 0.34 0.62 0.77 1.52 .001
Reference (0.02–0.70) (0.25–0.98) (0.40–1.13) (1.15–1.89)
Waist circumference, cm 95.24 95.46 96.51 97.42 99.87
Difference 0.00 0.86 1.63 2.11 3.86 .001
Reference (0.10–1.83) (0.65–2.61) (1.12–3.09) (2.86–4.85)
Total cholesterol, mg/dL 208.22 209.22 211.88 214.00 216.66
Difference 0.00 3.19 5.15 6.44 7.17 .001
Reference (0.68–7.06) (1.23–9.07) (2.50–10.38) (3.19–11.14)
Triglycerides, mg/dL 124.70 128.69 140.17 155.07 166.26
Difference 0.00 3.81 14.07 26.51 34.65 .001
Reference (5.85–13.48) (4.27–23.87) (16.66–36.37) (24.73–44.58)
HDL cholesterol, mg/dL 53.78 53.18 52.78 51.44 52.29
Difference 0.00 0.45 0.78 2.04 1.33 .002
Reference (1.62–0.73) (1.97–0.42) (3.24–0.84) (2.53–0.12)
LDL cholesterol, mg/dLa 129.97 130.51 131.83 132.38 132.48
Difference 0.00 2.62 3.45 3.39 2.08 .226
Reference (0.72–5.95) (0.06–6.85) (0.02–6.81) (1.37–5.53)
Systolic BP, mm Hg 124.95 125.70 126.57 126.76 128.17
Difference 0.00 1.04 1.55 1.41 2.03 .013
Reference (0.47–2.55) (0.03–3.08) (0.12–2.95) (0.48–3.58)
Diastolic BP, mm Hg 82.24 82.60 83.36 83.65 85.03
Difference 0.00 0.77 1.20 1.17 1.84 .001
Reference (0.21–1.75) (0.20–2.19) (0.16–2.17) (0.83–2.85)
Fasting glucose, mg/dL 96.54 96.80 98.26 98.18 100.37
Difference 0.00 0.40 1.31 0.77 2.09 .040
Reference (1.48–2.28) (0.60–3.21) (1.14–2.69) (0.15–4.02)
Log-HOMA-IR 0.22 0.25 0.28 0.37 0.48
Difference 0.00 0.03 0.05 0.11 0.19 .001
Reference (0.04–0.10) (0.02–0.12) (0.04–0.17) (0.12–0.26)
Abbreviation: BMI, body mass index.
The first line in each cell shows the raw mean. The second and third lines show the adjusted differences and their 95% CI calculated from a linear
model adjusted for age, history of blood donation, transaminases, and alcohol intake (Model 1). P trend values are calculated from a model
introducing ferritin quintiles because an ordinal variable.
a n  3313 due to missing values.
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.525), whereas at ferritin values between 100 and 300
g/L the odds of metabolic syndrome increased at a rate
of 1.23 per 50g/L of ferritin (P .001) ( Supplemental
Figure and Table). Adjustment of our models for CRP
did not substantially change the associations found.
Discussion
In this study of male Spanish workers, we found a positive
association between elevated iron stores and metabolic syn-
drome. Our results show that central obesity and hypertri-
Table 4. Adjusted OR (95% CI) for the Association of Serum Ferritin with Metabolic Syndrome and Defining
Criteria, Comparing the Lowest (1st) Ferritin Quintile with the Other Four Quintiles
Quintile of Ferritin Concentration (Interval in g/L)
1st
(<83)
2nd
(83–127)
3rd
(128–180)
4th
(181–261)
5th
(>261)
P
Trend
Central obesity MSCa 1.00 1.12 1.23 1.37 1.88 .001
(Reference) (0.87–1.45) (0.95–1.59) (1.06–1.77) (1.46–2.42)
Hypertriglyceridemia MSCa 1.00 1.09 1.23 1.86 2.15 .001
(Reference) (0.85–1.40) (0.96–1.58) (1.46–2.37) (1.69–2.74)
Low HDL cholesterol MSCa 1.00 0.90 0.90 1.20 1.18 .054
(Reference) (0.66–1.22) (0.67–1.23) (0.90–1.61) (0.88–1.58)
Hypertension MSC 1.00 1.12 1.22 1.22 1.41 .004
(Reference) (0.89–1.41) (0.96–1.54) (0.97–1.55) (1.11–1.79)
Hyperglycemia MSC 1.00 1.10 1.12 1.29 1.49 .001
(Reference) (0.87–1.40) (0.88–1.42) (1.01–1.64) (1.17–1.89)
Metabolic syndromea 1.00 0.91 1.11 1.52 1.92 .001
(Reference) (0.69–1.20) (0.84–1.45) (1.17–1.98) (1.48–2.49)
Cells show the adjusted ORs and their 95% CIs calculated from a logistic model adjusted for age, history of blood donation, transaminases, and
alcohol intake (Model 1). P trend values are calculated from a model introducing ferritin quintiles as an ordinal variable.
a n  3382 in these models all observations (4) with very high AST were decreased because they were all positive for the tested criterion.
Table 3. Adjusted Differences (95% CI) between the Lowest, (1st) Ferritin Quintile, and the Other Four Quintiles
for Continuous Variables Used in the Definition of Metabolic Syndrome, Adjusted for the Other Variables Associated
with the Syndrome
Variable
Quintile of Ferritin Concentration (Interval in g/L)
P
Trend
1st
(<83)
2nd
(83–127)
3rd
(128–180)
4th
(181–261)
5th
(>261)
Waist circumference, cma 0.00 0.61 1.15 1.40 3.01 .001
(Reference) (0.30–1.52) (0.22–2.08) (0.47–2.33) (2.06–3.95)
Triglycerides, mg/dLb 0.00 2.09 10.88 22.78 27.84 .001
(Reference) (7.44–11.61) (1.21–20.55) (13.05–32.50) (17.97–37.70)
HDL cholesterol, mg/dLb 0.00 0.23 0.34 1.49 0.29 .174
(Reference) (1.37–0.92) (1.50–0.83) (2.67–0.32) (1.48–0.90)
Systolic BP, mm Hgc 0.00 0.82 1.02 0.81 0.82 .368
(Reference) (0.66–2.30) (0.48–2.52) (0.70–2.33) (0.71–2.36)
Diastolic BP, mm Hgc 0.00 0.53 0.65 0.48 0.57 .349
(Reference) (0.41–1.48) (0.31–1.61) (0.49–1.44) (0.41–1.55)
Fasting glucose, mg/dLa 0.00 0.06 0.71 0.00 0.98 .392
(Reference) (1.79–1.91) (1.17–2.60) (1.90–1.90) (0.95–2.91)
Cells show the adjusted differences and their 95% CI calculated from a linear model adjusted for age, history of blood donation, transaminases,
and alcohol intake for all the variables.
a Further adjusted for the rest of the parameters.
b Further adjusted for waist circumference, systolic BP, diastolic BP, and fasting glucose.
c Further adjusted for waist circumference, triglycerides, HDL cholesterol, and fasting glucose (Model 2). P trend values are calculated from a model
introducing ferritin quintiles as an ordinal variable.
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glyceridemia are the main independent criteria associated
with elevated ferritin, and also show that the association has
a potential threshold, with an important association with
metabolic syndrome detected when serum ferritin levels are
between 100 and 300 g/L.
There has been considerable interest in the possibility
that excess iron stores contribute to the pathogenesis of
metabolic syndrome. Elevated serum ferritin levels have
been linked to different health conditions, such as hyper-
tension (4), central obesity (12), higher values of serum
triglycerides, and lower levels of HDL cholesterol (5, 6).
Iron overload is a predictor of abnormal glucose metab-
olism, obesity, and insulin resistance (7, 13, 14). Iron ac-
cumulates in human adipose tissue, and iron metabolism
is associated with insulin pathways there (15). Further-
more, adipocyte iron overload decreases adiponectin gene
expression in association with insulin resistance in mice
(16), and blood donation decreases glycosylated hemo-
globin and improves insulin resistance in subjects with
high ferritin and diabetes (17).
Most previous cross-sectional studies reported associ-
ations between iron stores and metabolic syndrome. Jehn
et al (2) reported an association in men between ferritin
and metabolic syndrome criteria, especially hyperglyce-
mia MSC and hypertriglyceridemia MSC. Yoo et al (18)
found an association with hyperglycemia MSC only in
men andwith triglyceridesMSCand lowHDL cholesterol
MSC only in women. Lee et al (19) found an association
between increased ferritin and hyperglycemia MSC and
hypertriglyceridemiaMSC only in men. Our results show
similar associations with hypertension MSC, central obe-
sity MSC, hypertriglyceridemia MSC and hyperglycemia
MSC, with steeper associations at serum ferritin levels
above 100g/L. This associationwas independent of age,
blood donation history, transaminases, and alcohol in-
take. Ferritin was also associated with insulin resistance
(measured as HOMA-IR).
Longitudinal studies related ferritin concentration pro-
spectively to the incidence of metabolic syndrome in
Frenchmenandwomen (20). Similarly, a5-year follow-up
study in Korean men found a strong and significant asso-
ciation of ferritin with the development of metabolic syn-
drome (21). These studies and our findings suggest that
high serum ferritin levels or iron metabolism may play a
causal role in the development of metabolic syndrome;
however, elevated serum ferritin could be cause or conse-
quence of metabolic syndrome, given that iron interferes
with insulin action in the liver and insulin stimulates iron
uptake by adipocytes and hepatocytes (22).
Ferritin, an intracellular protein, is an established bio-
marker of body iron stores (23). Iron and its homeostasis
are associated with the inflammatory response (24). In
hemochromatosis, liver injury is associated with impaired
insulin sensitivity in the liver and pancreatic dysfunction
(25–27). In animal models, iron participates in the forma-
tion of hydroxyl radicals, and an excess of ironmight lead
to cell oxidative stress, which can decrease insulin secre-
tory capacity (28). Several studies have demonstrated that
hepatic iron overload induces liver damage through the
production of malonyldialdehyde in the lipid peroxida-
tion in nonalcoholic fatty liver disease. This metabolite
canactivatehepatic stellate cells, themajor contributors to
fibrogenesis (29, 30). Our observations show that above a
certain threshold, increases in ferritin are associated with
metabolic impairment, suggesting that the metabolic dis-
order in hemochromatosis might be part of a progressive
continuum starting at lower iron levels. The only contin-
uous metabolic syndrome variables independently asso-
ciated with ferritin were waist circumference and triglyc-
erides. Ferritin is associated with triglycerides even in the
absence of metabolic syndrome (31), and triglycerides de-
crease after therapeutic phlebotomy, independently of
basal blood glucose (32). These observations suggest that
obesity might be an additional factor inducing functional
hepatic changes associated with an increase in iron and
hepatic triglyceride deposits. Individuals in advanced
stages of obesity and metabolic syndrome develop nonal-
coholic fatty liver disease, which may further elevate
transaminase levels (29, 30). Ferritin is also elevated in
acute and chronic hepatitis as a consequence of liver dam-
age (33, 34). We adjusted our analysis for transaminases
to avoid confusion with other causes of hepatic damage.
Our data suggest that ferritin has potential as an early
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Figure 1. Adjusted ORs (95% CIs) for the association of metabolic
syndrome with ferritin concentration. Ferritin was modeled as
restricted cubic splines with knots at the percentiles 5, 27.5, 50, 72.5,
and 95 of its distribution. The multivariable logistic regression model
was adjusted for age, history of blood donation, transaminases, and
alcohol intake (Model 1). The odds for metabolic syndrome at the 20th
percentile (82 g/L) of the ferritin distribution were used as a
reference. The histogram shows the distribution of ferritin
concentrations in the study sample.
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marker of parenchymal damage in obesity and metabolic
syndrome.
If we accept that iron predisposes metabolic syndrome,
future confirmation of the 100 ug/L thresholdmay help to
identify patients who would benefit from interventions
that target iron. This would require the development of
therapies able to modulate body iron at this near-normal
level. Even in caseswhere iron is elevated as a consequence
of liver damage brought about by intense metabolic-syn-
drome related injury, the restriction of the association to
the higher ferritin range may hint that the presence of this
elevation signals a more intense damage derived from the
metabolic disturbances, and this could inform decisions
aboutwhether to increase the intensity of therapy formet-
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Figure 2. Adjusted ORs (95% CIs) for the association of metabolic syndrome criteria with ferritin concentration. Ferritin was modeled as restricted
cubic splines with knots at the percentiles 5, 27.5, 50, 72.5, and 95 of its distribution. The multivariable logistic regression model was adjusted for
age, history of blood donation, transaminases, and alcohol intake (Model 1). The odds for metabolic syndrome at the 20th percentile (82 g/L) of
the ferritin distribution were used as a reference. The histogram shows the distribution of ferritin concentrations in the study sample.
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abolic syndrome in those particular subjects. Considering
that two thirds of our sample had ferritin above 100g/L,
these results suggest the need for studies to better define
the optimal tissue iron level among the broad range of
normal values, and the feasibility of manipulating body
iron.
Ferritin is an acute phase reactant, among others like
CRP. In our analysis, we excluded participants with high
CRP, thus discarding those with acute phase responses.
Nonetheless, metabolic syndrome and obesity are associ-
ated with the development of chronic, low-level inflam-
mation. Indeed, levels of CRP are mildly elevated in
metabolic syndrome (35). Adipose tissue releases proin-
flammatory mediators (36) that induce hepatic produc-
tion of CRP (37). However, our sensitivity analysis ad-
justing for CRP indicated that this inflammation pathway
has only a minor influence on the described associations.
Strengths of this study include the use of data from a
cohort that has been studied using strict procedures, both
in the collection of data and biological samples, which
meet the criteria for quality certification. Limitations in-
clude not having performed identification of a genetic
cause underlying high ferritin concentrations and the re-
striction of the study to men. In addition, the study has a
cross-sectional design making it impossible to infer cau-
sation.Differences inage, transaminase levels, andalcohol
intake between thosewithmetabolic syndrome andwithout
it could act as potential confounders for the association.
However, adjustment of our analysis for these variables pro-
vided differences and ORs that show associations indepen-
dent of age, hepatic cytolysis, and alcohol intake. We de-
signed the linear spline knots based solely on visual
inspection of the restricted cubic spline. We produced our
inferences and adjusted our methods to account for these
limitations.
Our results show that serum ferritin is associated with
metabolic syndrome,with independent association shown
for the diagnostic criteria central obesityMSC and hyper-
triglyceridemiaMSC.Theassociationwith the riskofmet-
abolic syndrome is seen only above a ferritin concentra-
tion of approximately 100 g/L (percentile 27.7). Future
studies should be considered to demonstrate the potential
of serum ferritin as an early marker of the metabolic dam-
age associated with the development of metabolic syn-
drome. Serum ferritin might be a particularly valuable
marker when levels are between 100 and 300 g/L.
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